Zoetis Inc. $ZTS Shares Sold by GSB Wealth Management LLC

GSB Wealth Management LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% during the second quarter, Holdings Channel reports. The firm owned 8,006 shares of the company’s stock after selling 432 shares during the period. GSB Wealth Management LLC’s holdings in Zoetis were worth $1,249,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Portside Wealth Group LLC raised its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its position in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC raised its holdings in shares of Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after buying an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new stake in shares of Zoetis during the first quarter valued at approximately $380,000. Finally, Soros Capital Management LLC raised its holdings in shares of Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after buying an additional 4,230 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE ZTS opened at $144.73 on Tuesday. The stock has a market capitalization of $64.14 billion, a P/E ratio of 24.91, a P/E/G ratio of 2.34 and a beta of 0.88. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $197.51. The business’s fifty day moving average is $151.03 and its two-hundred day moving average is $156.27. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the company earned $1.56 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.